Bank of New York Mellon Corp Sells 17,826 Shares of United Therapeutics Corporation $UTHR

Bank of New York Mellon Corp cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 333,629 shares of the biotechnology company’s stock after selling 17,826 shares during the quarter. Bank of New York Mellon Corp’s holdings in United Therapeutics were worth $162,561,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in UTHR. Goldman Sachs Group Inc. lifted its holdings in United Therapeutics by 27.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,774 shares of the biotechnology company’s stock worth $53,975,000 after purchasing an additional 23,938 shares in the last quarter. Westpac Banking Corp purchased a new position in United Therapeutics in the 4th quarter worth approximately $719,000. Peak Retirement Planning Inc. purchased a new position in United Therapeutics in the 4th quarter worth approximately $2,719,000. Natixis Advisors LLC lifted its holdings in United Therapeutics by 0.5% in the 4th quarter. Natixis Advisors LLC now owns 11,768 shares of the biotechnology company’s stock worth $5,734,000 after purchasing an additional 53 shares in the last quarter. Finally, Florida Financial Advisors LLC lifted its holdings in United Therapeutics by 5.4% in the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Finally, UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $619.42.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,323.93. This represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,712,246.04. This trade represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 624,043 shares of company stock valued at $351,649,680 in the last ninety days. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $549.87 on Friday. The stock has a market capitalization of $23.34 billion, a price-to-earnings ratio of 20.30, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The business’s 50 day simple moving average is $568.23 and its 200-day simple moving average is $518.83.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the company earned $6.63 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.